Emergent BioSolutions Announces Successful Completion of Offering of 3.875% Senior Unsecured Notes Due 2028
07 août 2020 16h05 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has completed its previously announced offering of $450 million in...
Emergent BioSolutions Announces Upsize and Pricing of $450 Million of 3.875% Senior Unsecured Notes Due 2028
04 août 2020 18h31 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has priced its offering of $450 million aggregate principal amount...
Emergent BioSolutions Announces Proposed Offering of $400 Million of Senior Unsecured Notes
04 août 2020 08h00 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it intends to offer $400 million aggregate principal amount of senior...
Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2020 and Revises Upward Full Year 2020 Guidance
30 juil. 2020 16h27 HE
|
Emergent BioSolutions
Establishes key collaborations with industry, U.S. government, and health care providers to help advance COVID-19 vaccine and therapeutic solutionsCurrent quarter and year-to-date performance reflect...
Emergent BioSolutions Inc. to be Added to the S&P MidCap 400 Index
21 juil. 2020 16h45 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., July 21, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Standard & Poor’s (S&P) has indicated that the company will be added to the...
Emergent BioSolutions to Participate in Virtual Investor Conferences
16 juin 2020 16h05 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., June 16, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following...
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca’s COVID-19 Vaccine Candidate
11 juin 2020 08h47 HE
|
Emergent BioSolutions
Emergent will provide contract development and manufacturing services and secure large-scale manufacturing capacity through 2020 to support AstraZeneca’s COVID-19 vaccine candidateAgreement valued at...
Emergent BioSolutions to Participate in Virtual Investor Conferences
12 mai 2020 06h00 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., May 12, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following...
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 21, 2020 at 9:00am EDT
07 mai 2020 09h20 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., May 07, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2020 Annual Meeting of Stockholders will be held in a virtual-only format via live...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2019 Financial Results and Conduct a Conference Call on February 20, 2020
03 févr. 2020 16h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 20, 2020 at 5:00 pm (Eastern Time) to discuss the...